Faculty
Professor, Departments of Biostatistics and Epidemiology, Boston University, School of Public Health; Director, MA in Clinical Investigation, Boston University School of Medicine
Dr. Fish has a long history of research in the areas of clinical toxicology and emergency medicine. She has most recently focused on research ethics in general, and application of the federal regulations for waiver of informed consent in certain emergency research circumstances. Issues relating to the design of clinical research and ethical implications of study designs are Dr. Fish’s areas of expertise.
She is the former director of the IRB for the Boston University Medical Campus and Boston Medical Center. She is currently a member of the US Environmental Protection Agency’s Human Studies Review Board.
Adjunct Assistant Professor, School of Medicine
Dr. Gloff develops strategies for rapidly moving medical products through the non-clinical and clinical trials process to marketing approval by the US Food and Drug Administration and international regulatory agencies. Dr. Gloff’s scientific expertise encompasses clinical and non-clinical pharmacokinetics, non-clinical toxicology, chemistry, manufacturing and control issues, and clinical operations.
Dr. Gloff is a former member of the Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology of the FDA’s Center for Drug Evaluation and Research.
Lecturer, Boston University School of Medicine
Dr. Guo’s research interests include conduct and analysis of various biomedical research projects including general biostatistics, cross sectional and longitudinal studies, multivariate and survival analyses.
His special interest is statistical genetics including linkage and/or association mapping and missing data studies.
Adjunct Assistant Professor, Boston University, School of Medicine
With over 22 years of experience in clinical affairs management with contract research organizations and biotechnology companies, Laurie is recognized as an industry expert in improving the organizational effectiveness of clinical research programs with a specialty in gap analysis and strategic planning. Laurie has executed over 25 clinical trials from Phase 1 to Phase 3 for both emerging and established companies and has managed operational budgets of up to $24 MM. Prior to founding Halloran Consulting Group, Laurie spent 10 years at PAREXEL International where she developed worldwide training capabilities with the clinical operations group. She has also established clinical operations at OXiGENE and Antigenics.
Ms. Halloran’s primary research interest is pharmaceutical business process improvement.
Adjunct Assistant Professor, Department of Epidemiology, Boston University School of Public Health. Dr. McNair most recently, was senior medical director in clinical development and medical affairs at vertex pharmaceuticals
Her research interests include clinical research ethics and research subject protection, ethical industry-sponsored drug development research, and interactions between Institutional Review Boards and the pharmaceutical industry.
Associate Provost, Boston University Medical Campus; Director, Office of Clinical Research, Boston University Medical Center; Professor of Medicine, Boston University School of Medicine.
Dr. Moore is interested in the effect of foods on blood pressure and cardiac risk, dietary approaches to stop hypertension, and changing health behaviors via the internet. He is the author of The DASH Diet for Hypertension, a diet clinically proven to lower blood pressure levels and thereby reduce the risk of heart failure, stroke and kidney disease.
Professor of Pharmacology, Boston University School of Medicine
Dr. Walsh’s research interests include gastrointestinal pharmacology, the toxicology of metal compounds, and pharmacokinetics. Projects have included the elucidation of the hypocholesterolemic effect of pharmacologic agents, evaluation of the gastrointestinal toxicity of lead, and a critical review of the toxicology of zinc.
Pharmacokinetic studies have included work with opiate analgesics, phenothiazines, pyrimidine and purine analogue anticancer agents, antiepileptic agents, mercury-containing compounds, and butyric acid derivatives for sickle cell anemia and thalessemias.
Adjunct Lecturer
Ms. Yashon has a background in Law and Ethics and a specialty in genetics. She has developed activities for putting bioethics in the science classroom and has a number of published books on that topic and landmark legal cases as they apply to science. The legal and ethical background of clinical research is also an interest of hers and she has written articles on the history of the use of human subjects in experimentation.
She is currently researching how legal education is addressing these issues.
